BOLDEN THERAPEUTICS TO PRESENT AT THE 3RD ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT
PROVIDENCE, R.I. and BOSTON, June 8, 2023 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation to present at the 3rd Annual Oligonucleotides for CNS Summit on June 6th-8th in Boston, MA.